GET DAILY SIGNALSAstraZeneca (AZN) Delivers Q2 2026 Core EPS Beat with Oncology Momentum
Key Takeaways
- Core EPS beat consensus handsomely: Q2 2026 core earnings per share (EPS) reached $2.63, up 21% year-over-year and well above the company-compiled consensus of $2.49.
- Revenue landed in line with expectations: Total revenue of $15.38 billion rose 6% from a year ago and matched the $15.39 billion consensus forecast.
- Oncology remained the standout growth engine: Oncology revenue surged 16% to $7.33 billion, driven by Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu.
- Farxiga headwinds materialized as expected: The Cardiovascular, Renal & Metabolism (CVRM) segment declined 15%, reflecting the US loss of exclusivity for blockbuster drug Farxiga.
- Full-year 2026 guidance reaffirmed: Management maintained its outlook for mid-to-high single-digit revenue growth and low double-digit core EPS growth at constant exchange rates (CER).
- Pipeline news was mixed: A gastric cancer trial met its primary endpoint, but Ultomiris failed a Phase III study in stem-cell transplant patients, adding to earlier disappointment from the Wainua CARDIO-TTRansform trial.
Why This Quarter Matters for AstraZeneca
This quarterly report arrived at a sensitive moment for AZN. Earlier in July, shares tumbled after the company disclosed that its nerve drug Wainua failed to meet the primary endpoint in the CARDIO-TTRansform late-stage trial, a setback that wiped more than 11% off the company's market valuation and raised doubts about its ability to achieve the ambitious $80 billion annual revenue target set for 2030. With the stock already down roughly 8% year-to-date heading into the report, investors were watching closely for signs that AstraZeneca's core oncology and rare disease franchises could sustain enough momentum to offset pipeline disappointments and the ongoing erosion of Farxiga sales following the loss of US market exclusivity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
AstraZeneca reported total revenue of $15.38 billion for the second quarter ended June 30, 2026, a 6% increase on a reported basis and 5% at CER compared with $14.46 billion in the prior-year period. Revenue was essentially in line with the company-compiled consensus of $15.39 billion. For the first half of 2026, total revenue reached $30.67 billion, up 9% from $28.05 billion in H1 2025.
On the bottom line, core EPS of $2.63 surged 21% year-over-year (18% at CER), comfortably exceeding the consensus estimate of $2.49. The beat was partly attributed to a lower effective tax rate during the quarter. Reported (GAAP) EPS came in at $1.61, a 2% increase from $1.58 a year ago. For the half-year, core EPS rose 12% to $5.21, while reported EPS increased 4% to $3.60.
Segment performance told a tale of two businesses. Oncology delivered a 16% revenue increase to $7.33 billion, powered by strong demand across Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. Rare Disease grew 9%, supported by Ultomiris and Soliris. By contrast, the BioPharmaceuticals unit, which includes CVRM and Respiratory & Immunology, saw revenue decline 5% to $5.33 billion, with CVRM dropping 15% as Farxiga faced generic competition in the US. China revenue fell 7%, pressured by volume-based procurement policies, while US revenue rose 6% and Emerging Markets excluding China jumped 14%. From what I see, the oncology numbers continue to stand out as the key support for the growth narrative.
Pretax profit fell 11% to $2.80 billion, reflecting higher operating costs. The company declared an interim dividend of $1.06 per share, up from $1.03 a year ago, and stated its intention to raise the full-year dividend to $3.30 per share.
Market Reaction and Investor Sentiment
AstraZeneca shares rose approximately 1.5% to 1.7% in early trading on Monday following the release, briefly touching their highest level since the Wainua trial failure earlier in July. The positive reaction reflected relief that core earnings meaningfully surpassed expectations and that management held firm on both the 2026 outlook and the 2030 $80 billion revenue ambition. CEO Pascal Soriot struck a confident tone, stating that the company remains "on track to deliver our $80 billion Total Revenue ambition, which assumes successes and setbacks," while pointing to more than twenty high-value clinical readouts expected over the next 18 months. Analysts at JPMorgan described the quarter as "solid" and indicated that AstraZeneca remains capable of reaching its long-term revenue goal. However, the mixed pipeline updates — including the Ultomiris Phase III miss in transplant-associated thrombotic microangiopathy (a rare and serious blood-clotting complication) — kept some caution in the air, and the stock remains well below its 52-week high of $212.71.
Forward Outlook and Key Factors to Monitor
AstraZeneca heads into the second half of 2026 with its financial guidance intact but its pipeline under heightened scrutiny. The company expects total revenue to grow by a mid-to-high single-digit percentage and core EPS to increase by a low double-digit percentage at CER for the full year. A potential low single-digit currency tailwind could provide an additional lift if exchange rates hold at current levels.
The most critical near-term catalysts center on the clinical pipeline. Two upcoming late-stage cancer readouts — the SERENA-4 breast cancer study and the AVANZAR lung cancer trial testing a combination of Datroway and Imfinzi — will serve as litmus tests for investor confidence in AstraZeneca's research and development (R&D) productivity following the Wainua setback. Management also flagged tozorakimab as a potential $5 billion-plus respiratory opportunity ahead of an upcoming data presentation, a notable upgrade from prior estimates of around $3 billion.
On the commercial front, the trajectory of Oncology and Rare Disease remains central to the growth story. Tagrisso, Imfinzi, Calquence, and Enhertu must continue generating double-digit gains to compensate for the ongoing decline in Farxiga revenue and pricing headwinds in China. Investors should also monitor the company's $15 billion commitment to expand R&D operations in China, a strategic bet that carries both significant upside potential and geopolitical risk in an increasingly complex regulatory environment.
The newly raised dividend and the company's reiterated long-term ambition underscore management's confidence, but execution across both the pipeline and commercial portfolio will determine whether AstraZeneca can regain the market's full trust in the quarters ahead. One thing that stands out is how the reaffirmed guidance provides a steady anchor even as pipeline news remains mixed.
Using Tickeron’s AI Screener in My Research
As part of my ongoing analysis, I often turn to Tickeron’s AI Screener to scan the pharmaceutical sector and identify comparable opportunities. The tool lets me apply filters for earnings momentum, technical patterns, and industry metrics, which helps surface ideas more efficiently than manual reviews alone. It has become a regular part of how I cross-check company results against broader market trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
AZN's Stochastic Oscillator reaching overbought zone
The Stochastic Oscillator for AZN moved into overbought territory on October 16, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for AZN crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
The 50-day moving average for AZN moved below the 200-day moving average on September 18, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AZN as a result. In 47 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
The Moving Average Convergence Divergence (MACD) for AZN just turned positive on October 15, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in 29 of 43 cases over the following month. The odds of a continued upward trend are 67%.
AZN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in 191 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
AZN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 19 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.101) is normal, around the industry mean (-4.339). P/E Ratio (24.542) is within average values for comparable stocks, (20.755). Projected Growth (PEG Ratio) (1.168) is also within normal values, averaging (5.738). Dividend Yield (0.026) settles around the average of (0.041) among similar stocks. P/S Ratio (4.148) is also within normal values, averaging (4.033).
The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement